Kinaset Therapeutics

Based in the US, Kinaset Therapeutics, Inc.Kinaset Therapeutics, Inc. was founded in 2020 by CEO Robert Clarke, COO Roger Heerman, and CDO Frazer Morgan in Massachusetts, US. The company specializes in inhaled therapeutics for severe asthma patients. In January 2026, Kinaset Therapeutics, Inc. Kinaset Therapeutics focuses on developing innovative inhaled therapeutics for patients suffering from severe asthma, specifically through its lead product, KN-002. This product is designed to treat all patients with severe asthma, targeting the underlying inflammation regardless of its cause. KN-002 utilizes a novel, non-invasive anti-inflammatory approach that allows for the direct delivery of medication to the lungs, minimizing systemic exposure and enhancing the therapeutic impact at the site of need. The primary end users of this product are individuals diagnosed with severe asthma, who are seeking more effective treatment options to manage their condition.Kinaset Therapeutics operates within a structured revenue model that includes partnerships with healthcare providers and distributors focused on respiratory therapeutics. The company’s transactions involve direct sales to healthcare facilities and potentially retail pharmacies, where KN-002 is made available to patients through prescription. While specific pricing for KN-002 and associated services are not disclosed, the revenue generation is fundamentally linked to the successful adoption and sales of this flagship product in the healthcare marketplace. The firm’s revenue framework is supported by the increasing need for effective asthma treatments, which underscores the growth potential in this sector. In January 2026, Kinaset Therapeutics, Inc.

1. Series B

   Jan 10, 2026

   Amount

   $103M

   Investors

   Locked

2. Series A

   Nov 30, 2020

   Amount

   $40M

   Investors

   Locked